- Home
- GLAD vs REPL Comparison
GLAD vs REPL Comparison
Compare GLAD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- REPL
- Stock Information
- Founded
- GLAD 2001
- REPL 2015
- Country
- GLAD United States
- REPL United States
- Employees
- GLAD N/A
- REPL N/A
- Industry
- GLAD Finance/Investors Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- REPL Health Care
- Exchange
- GLAD Nasdaq
- REPL Nasdaq
- Market Cap
- GLAD 482.1M
- REPL 547.0M
- IPO Year
- GLAD N/A
- REPL 2018
- Fundamental
- Price
- GLAD $19.24
- REPL $8.54
- Analyst Decision
- GLAD Hold
- REPL Buy
- Analyst Count
- GLAD 2
- REPL 9
- Target Price
- GLAD $25.75
- REPL $12.00
- AVG Volume (30 Days)
- GLAD 290.6K
- REPL 8.9M
- Earning Date
- GLAD 11-17-2025
- REPL 11-07-2025
- Dividend Yield
- GLAD 10.85%
- REPL N/A
- EPS Growth
- GLAD N/A
- REPL N/A
- EPS
- GLAD 3.38
- REPL N/A
- Revenue
- GLAD $88,900,000.00
- REPL N/A
- Revenue This Year
- GLAD N/A
- REPL N/A
- Revenue Next Year
- GLAD $16.05
- REPL N/A
- P/E Ratio
- GLAD $5.68
- REPL N/A
- Revenue Growth
- GLAD N/A
- REPL N/A
- 52 Week Low
- GLAD $18.90
- REPL $2.68
- 52 Week High
- GLAD $30.43
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GLAD 32.84
- REPL 57.42
- Support Level
- GLAD $19.00
- REPL $8.26
- Resistance Level
- GLAD $19.51
- REPL $10.85
- Average True Range (ATR)
- GLAD 0.44
- REPL 0.82
- MACD
- GLAD 0.14
- REPL 0.03
- Stochastic Oscillator
- GLAD 30.41
- REPL 61.64
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.